NCT00365391View on ClinicalTrials.gov

Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

August 31, 2008

Study Completion Date

June 30, 2010

Conditions
Adult Primary Hepatocellular CarcinomaAdvanced Adult Primary Liver CancerLocalized Unresectable Adult Primary Liver CancerRecurrent Adult Primary Liver Cancer
Interventions
BIOLOGICAL

bevacizumab

Given IV, 10 mg/kg, days 1 and 15 in every cycle

DRUG

erlotinib hydrochloride

Given orally, 150 mg, every day during each cycle.

Trial Locations (1)

55905

Mayo Clinic, Rochester

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00365391 - Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer | Biotech Hunter | Biotech Hunter